CO6140059A2 - Derivados de imidazol-pirimidina para el tratamiento de enfermedades relacionadas con la glicogeno sintasa quinasa (gsk3) - Google Patents
Derivados de imidazol-pirimidina para el tratamiento de enfermedades relacionadas con la glicogeno sintasa quinasa (gsk3)Info
- Publication number
- CO6140059A2 CO6140059A2 CO08134161A CO08134161A CO6140059A2 CO 6140059 A2 CO6140059 A2 CO 6140059A2 CO 08134161 A CO08134161 A CO 08134161A CO 08134161 A CO08134161 A CO 08134161A CO 6140059 A2 CO6140059 A2 CO 6140059A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- optionally substituted
- halo
- cyano
- alkoxy
- Prior art date
Links
- KNDAOVHRTCJABP-UHFFFAOYSA-N 1h-imidazole;pyrimidine Chemical class C1=CNC=N1.C1=CN=CN=C1 KNDAOVHRTCJABP-UHFFFAOYSA-N 0.000 title 1
- 102000001267 GSK3 Human genes 0.000 title 1
- 108060006662 GSK3 Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 title 1
- 125000005843 halogen group Chemical group 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- -1 3-tetrahydropyranyl Chemical group 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 abstract 1
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1.- Un compuesto de fórmula (I):En donde:R1 se selecciona de sulfamoilo, carbamoilo, un grupo -R5-R6 y un anillo saturado de 4-7 miembros unido a nitrógeno, el cual opcionalmente contiene un átomo de nitrógeno, oxígeno o azufre adicional; en donde dicho anillo está opcionalmente sustituido en el carbono por uno o más R7; y en donde si dicho anillo contiene un átomo de nitrógeno adicional ese nitrógeno está opcionalmente sustituido por R8; al menos uno de X1, X2, X3 y X4 se selecciona de N, los otros tres X1, X2, X3 o X4 se seleccionan independientemente de N o C(R9), con la condición que no más de dos de X1, X2, X3 o X4 se seleccionan de N; R2 es halo o ciano; R3 es metilo, 3-tetrahidropiranilo o 4-tetrahidropiranilo, en donde el grupo tetrahidropiranilo está opcionalmente sustituido en el carbono por uno o más R10; R4 se selecciona de hidrógeno, halo, ciano y alquilo C1-3, en donde alquilo C1-3 está opcionalmente sustituido con uno o más halo; R5 se selecciona de -O-, -C(O)-, -C(O)O-, -C(O)N(R11)-, -S(O)r- y -SO2N(R12)-; en donde R11 y R12 se seleccionan independientemente de hidrógeno o alquilo C1-6 y dicho alquilo está opcionalmente sustituido por uno o más R13; y r es 0, 1 ó 2; R6 se selecciona de alquilo C1-6, carbociclilo y heterociclilo; en donde R6 está opcionalmente sustituido en el carbono por uno o más R14; y en donde si dicho heterociclilo contiene un fragmento-NH- ese nitrógeno está opcionalmente sustituido por un grupo seleccionado de R15;R7 se selecciona de halo, ciano, hidroxi, trifluorometoxi, alcoxi C1-3 y alquilo C1-3, en donde dicho alquilo C1-3 está opcionalmente sustituido por uno o más halo;R9 se selecciona de hidrógeno, halo, ciano, hidroxi, amino, alquilo C1-3 y alcoxi C1-3; R10, R13 y R14 se seleccionan independientemente de halo, ciano, hidroxi, amino, sulfamoilo, alquilo C1-6, alcoxi C1-6, alcoxi C1-6 alcoxi C1-6, N-(alquil C1-6)amino, N,N-(alquil C1-6)2amino, alcanoilamino C1-6, N-(alquil C1-6)carbamoilo, ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81675606P | 2006-06-27 | 2006-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6140059A2 true CO6140059A2 (es) | 2010-03-19 |
Family
ID=38846127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO08134161A CO6140059A2 (es) | 2006-06-27 | 2008-12-17 | Derivados de imidazol-pirimidina para el tratamiento de enfermedades relacionadas con la glicogeno sintasa quinasa (gsk3) |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20080188502A1 (es) |
| EP (1) | EP2046782A4 (es) |
| JP (1) | JP2009542638A (es) |
| KR (1) | KR20090024817A (es) |
| CN (1) | CN101511825A (es) |
| AR (1) | AR061652A1 (es) |
| AU (1) | AU2007265731A1 (es) |
| BR (1) | BRPI0713576A2 (es) |
| CA (1) | CA2655441A1 (es) |
| CL (1) | CL2007001881A1 (es) |
| CO (1) | CO6140059A2 (es) |
| EC (1) | ECSP088973A (es) |
| IL (1) | IL195666A0 (es) |
| MX (1) | MX2008015720A (es) |
| NO (1) | NO20090327L (es) |
| RU (1) | RU2008148902A (es) |
| TW (1) | TW200815418A (es) |
| UY (1) | UY30440A1 (es) |
| WO (1) | WO2008002244A2 (es) |
| ZA (1) | ZA200810484B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2623374A1 (en) | 2005-09-30 | 2007-04-05 | Astrazeneca Ab | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
| AR058073A1 (es) * | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos |
| TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| TW200815417A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
| DK2041123T3 (da) * | 2006-06-27 | 2012-05-07 | Takeda Pharmaceutical | Kondenserede cykliske forbindelser. |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2406230A1 (en) | 2009-03-11 | 2012-01-18 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
| UY32562A (es) | 2009-04-15 | 2010-11-30 | Astrazeneca Ab | Pirimidinas sustituidas por imidazol 724 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN103724207B (zh) * | 2013-12-20 | 2016-07-06 | 北京智博高科生物技术有限公司 | 苯基苄基醚类衍生物及其制备方法和应用 |
| JP2017524739A (ja) | 2014-07-17 | 2017-08-31 | アンセルムＩｎｓｅｒｍ | 神経筋接合部関連疾患の処置方法 |
| UY36547A (es) | 2015-02-05 | 2016-06-01 | Bayer Cropscience Ag | Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas |
| WO2016207366A1 (en) | 2015-06-26 | 2016-12-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of viral infections |
| MX2018001417A (es) | 2015-08-07 | 2018-03-15 | Bayer Cropscience Ag | Derivados heterociclicos condensados sustituidos por 2-(het)-arilo como pesticidas. |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| CA2491895C (en) * | 2002-07-09 | 2011-01-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| EP1648887A1 (en) * | 2003-07-30 | 2006-04-26 | Cyclacel Limited | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors |
| AU2004285745A1 (en) * | 2003-10-21 | 2005-05-12 | Cyclacel Limited | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy |
| GB0402653D0 (en) * | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| BRPI0517426A (pt) * | 2004-12-17 | 2008-10-07 | Astrazeneca Ab | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito anti-proliferação celular, para produzir um efeito inibitório de cdk2, e para tratar uma doença em um animal de sangue quente |
| GB0504753D0 (en) * | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| AR058073A1 (es) * | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos |
| TW200815417A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
-
2007
- 2007-06-21 TW TW096122338A patent/TW200815418A/zh unknown
- 2007-06-26 AU AU2007265731A patent/AU2007265731A1/en not_active Abandoned
- 2007-06-26 JP JP2009518044A patent/JP2009542638A/ja active Pending
- 2007-06-26 KR KR1020097001642A patent/KR20090024817A/ko not_active Withdrawn
- 2007-06-26 UY UY30440A patent/UY30440A1/es unknown
- 2007-06-26 WO PCT/SE2007/000620 patent/WO2008002244A2/en not_active Ceased
- 2007-06-26 EP EP07748281A patent/EP2046782A4/en not_active Withdrawn
- 2007-06-26 BR BRPI0713576-9A patent/BRPI0713576A2/pt not_active IP Right Cessation
- 2007-06-26 CL CL200701881A patent/CL2007001881A1/es unknown
- 2007-06-26 CA CA002655441A patent/CA2655441A1/en not_active Abandoned
- 2007-06-26 RU RU2008148902/04A patent/RU2008148902A/ru not_active Application Discontinuation
- 2007-06-26 MX MX2008015720A patent/MX2008015720A/es not_active Application Discontinuation
- 2007-06-26 CN CNA2007800322107A patent/CN101511825A/zh active Pending
- 2007-06-26 AR ARP070102831A patent/AR061652A1/es not_active Application Discontinuation
- 2007-06-27 US US11/769,102 patent/US20080188502A1/en not_active Abandoned
-
2008
- 2008-12-02 IL IL195666A patent/IL195666A0/en unknown
- 2008-12-10 ZA ZA200810484A patent/ZA200810484B/xx unknown
- 2008-12-12 EC EC2008008973A patent/ECSP088973A/es unknown
- 2008-12-17 CO CO08134161A patent/CO6140059A2/es unknown
-
2009
- 2009-01-21 NO NO20090327A patent/NO20090327L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007265731A1 (en) | 2008-01-03 |
| CL2007001881A1 (es) | 2008-02-08 |
| TW200815418A (en) | 2008-04-01 |
| MX2008015720A (es) | 2008-12-19 |
| ECSP088973A (es) | 2009-01-30 |
| CA2655441A1 (en) | 2008-01-03 |
| US20080188502A1 (en) | 2008-08-07 |
| IL195666A0 (en) | 2009-09-01 |
| KR20090024817A (ko) | 2009-03-09 |
| EP2046782A2 (en) | 2009-04-15 |
| ZA200810484B (en) | 2009-08-26 |
| WO2008002244A8 (en) | 2008-10-09 |
| UY30440A1 (es) | 2008-01-31 |
| NO20090327L (no) | 2009-02-09 |
| AR061652A1 (es) | 2008-09-10 |
| WO2008002244A3 (en) | 2008-02-14 |
| JP2009542638A (ja) | 2009-12-03 |
| EP2046782A4 (en) | 2010-10-13 |
| RU2008148902A (ru) | 2010-08-10 |
| CN101511825A (zh) | 2009-08-19 |
| WO2008002244A2 (en) | 2008-01-03 |
| BRPI0713576A2 (pt) | 2012-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6140059A2 (es) | Derivados de imidazol-pirimidina para el tratamiento de enfermedades relacionadas con la glicogeno sintasa quinasa (gsk3) | |
| AR044152A1 (es) | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad | |
| EA200970478A1 (ru) | Аналоги тиофена для лечения или предупреждения флавивирусных инфекций | |
| CO5640098A2 (es) | Acidos biariloximetilaren-carboxilicos | |
| TW200615275A (en) | Hepatitis C inhibitor dipeptide analogs | |
| AR062797A1 (es) | Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas. | |
| AR062640A1 (es) | Compuestos de azolcarboxamidas y composiciones herbicidas | |
| BRPI0606524A2 (pt) | derivados de indol para o tratamento de infecções virais | |
| BRPI0516735B8 (pt) | métodos para produção de (r)-2-acetamido-n-benzil-3-metoxipropionamida (lacosamida) e de uma formulação farmacêutica, e uso de (r)-n-benzil-2-nboc-amino-3-metoxipropionamida (c-937) | |
| BRPI0720993B8 (pt) | usos de compostos análogos de ciclopamina | |
| UA94602C2 (en) | Viral polymerase inhibitors | |
| EA200870460A1 (ru) | Производные циклогексилпиразол-лактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1 | |
| EA200970493A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| AR061653A1 (es) | Compuestos inhibidores de gsk3(glucogeno sintasa quinasa 3) | |
| EA201100189A1 (ru) | Гетероарильные производные в качестве ингибиторов dgat1 | |
| AR064521A1 (es) | Activador de glucoquinasa | |
| BR0307408A (pt) | Tripeptìdeos tendo um éter de hidroxipolina de uma quinolina substituìda para a inibição de ns3 (hepatite c) | |
| CU23926B1 (es) | Derivado de oxopirazina y herbicida | |
| AR065498A1 (es) | Co- critales de vx-950 (un inhibidor del virus de la hepatitis c) y composiciones farmaceuticas que los comprenden | |
| BRPI0610312B8 (pt) | dispositivo de assistência à caminhada | |
| AR042827A1 (es) | Compuestos de furano condensados | |
| NO20085107L (no) | Spirosykliske nitriler som proteaseinhibitorer | |
| BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
| AR073315A1 (es) | Compuestos heterociclicos antivirales | |
| MX2009004290A (es) | Inhibidores de proteasas de catepsina. |